Search
Contact
Shake It Up is supporting the Alfred Hospital Movement Disorders Program’s recruitment of patients for a phase one clinical trial in Parkinson’s disease. The trial is designed to explore a potential treatment that could shape the future care of people living with the condition.
Clinical trials like this are essential in unlocking the medical breakthroughs that could change the lives of more than 200,000 Australians living with Parkinson’s today, and all those diagnosed in the future.
About the trial
With support from The Michael J. Fox Foundation for Parkinson’s Research, Longevity Biotech Australia is developing a new medication that’s focused on modulating the immune system. The study is called Longevity: A Two-Part Single and Multiple Ascending Dose Trial of LBT-3627, and the researchers are investigating the safety and tolerability of LBT-3627. The trial will explore how this potential Parkinson’s medication acts in the body at different doses. This study has been approved by a Human Research Ethics Committee
What does participation involve?
If deemed eligible by the medical team, people taking part in the study will stay in the hospital briefly (fewer than 3 days), where they will receive the trial medication and undergo assessments, including a UPDRS exam, blood and urine testing. Participants will receive the trial medication once daily for up to 14 days, along with two follow-up visits at the end of the study. There will be various trial assessments throughout and the maximum on-study participation is 28 days. Participants will be remunerated for their time.
Who is eligible?
Inclusion criteria
To take part in this important trial, you must:
- Have been diagnosed with Parkinson’s disease within the last 10 years.
- Either not taking Parkinson’s medications or be on a stable dose of levodopa for at least three months.
- Be prepared to attend the hospital for the required consecutive visits, including an overnight stay for 2 to 3 nights.
Exclusion criteria
If any of the below applies to you, you will not be able to participate:
- Recent treatment for cancer (within the last 5 years).
- Currently pregnant or breastfeeding.
- Previous deep brain stimulation surgery.
- Ongoing infrared light therapy.
- Diagnosis of dementia.
- Smoking more than one pack per week.
- Regular use of cannabis or cannabidiol products.
Interested in taking part?
For more information about this study, contact the trials team at the Alfred Hospital at: +61 487 531 448 or Beth Sutherland (b.sutherland@alfred.org.au) or scan the QR code below to send an email.
